Does Elevated Asymmetrical Dimethylarginine Predict Major Adverse Cardiac Events and Mortality in Patients after Percutaneous Coronary Intervention?
Yang Shao,Yichuan Fan,Jun Li,Hui Cao,Bing Liu,Junpeng Wang,Jun Yang,Qiang Zhang,Xinhua Hu
DOI: https://doi.org/10.1016/j.ijcard.2014.10.121
IF: 4.039
2015-01-01
International Journal of Cardiology
Abstract:Percutaneous coronary interventions (PCI) have been proposed as a superior management strategy in patients with acute coronary syndrome, particularly in ST elevation myocardial infarction (MI). Despite the dramatic reduction in mortality associated with the use of PCI, cardiovascular mortality is still as high as 40% [[1]Stolker J.M. Cohen D.J. Lindsey J.B. Kennedy K.F. Kleiman N.S. Marso S.P. Mode of death after contemporary percutaneous coronary intervention: a report from the Evaluation of Drug Eluting Stents and Ischemic Events registry.Am. Heart J. 2011; 162: 914-921Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar]. Therefore, finding predictors for future adverse events after PCI is very important. Asymmetric dimethylarginine (ADMA) is a naturally occurring oxidative substance of the human plasma. ADMA has been recognized as a cardiovascular risk factor [2Boger R.H. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.Cardiovasc. Res. 2003; 59: 824-833Crossref PubMed Scopus (327) Google Scholar, 3Schulze F. Lenzen H. Hanefeld C. Bartling A. Osterziel K.J. Goudeva L. et al.Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study.Am. Heart J. 2006; 152 (e1-8): 493Abstract Full Text Full Text PDF PubMed Scopus (161) Google Scholar]. Several studies [4Lu T.M. Ding Y.A. Lin S.J. Lee W.S. Tai H.C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention.Eur. Heart J. 2003; 24: 1912-1919Crossref PubMed Scopus (170) Google Scholar, 5Cavusoglu E. Ruwende C. Chopra V. Yanamadala S. Eng C. Pinsky D.J. et al.Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography.Coron. Artery Dis. 2009; 20: 112-117Crossref PubMed Scopus (36) Google Scholar, 6Lu T.M. Chung M.Y. Lin M.W. Hsu C.P. Lin S.J. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography.Int. J. Cardiol. 2011; 153: 135-140Abstract Full Text Full Text PDF PubMed Scopus (65) Google Scholar, 7Sen N. Ozlu M.F. Akgul E.O. Kanat S. Cayci T. Turak O. et al.Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion.Atherosclerosis. 2011; 219: 304-310Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar, 8Meinitzer A. Kielstein J.T. Pilz S. Drechsler C. Ritz E. Boehm B.O. et al.Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.Clin. Chem. 2011; 57: 112-121Crossref PubMed Scopus (93) Google Scholar, 9Derkacz A. Protasiewicz M. Poreba R. Doroszko A. Poreba M. Antonowicz-Juchniewicz J. et al.Plasma asymmetric dimethylarginine predicts restenosis after coronary angioplasty.Arch. Med. Sci. 2010; 7: 444-448Google Scholar, 10Ari H. Ari S. Erdogan E. Tiryakioglu O. Ustundag Y. Huysal K. et al.A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine.Heart Vessels. 2010; 25: 19-26Crossref PubMed Scopus (10) Google Scholar] have addressed the ability of ADMA level to predict subsequent cardiovascular events and mortality in patients undergoing PCI. Considering a small number of sample sizes may be lack of power to reveal the reliable conclusion, we conducted a meta-analysis to investigate the relationship of baseline ADMA level and future MACEs and mortality event based on the prospective studies. We conducted a PubMed database and Embase search prior to May 2014. The following search keywords were used: ADMA or asymmetric dimethylarginine and mortality or death or major adverse cardiac events (MACEs) and stent or PCI or percutaneous coronary interventions. Studies were considered eligible if: 1) prospective observational studies; 2) patients undergoing PCI and follow-up at least one year; and 3) providing adjusted hazard ratio (HR) and corresponding 95% confidence interval (CI) of MACEs and cardiovascular or all-cause mortality comparing the highest to lowest baseline ADMA category. MACEs are defined as non-fatal myocardial infarction, in-stent thrombosis, total stroke, coronary heart disease mortality, target vessel revascularization, and cardiovascular mortality. Restenosis was defined as the diameter stenosis more than 50% both within the stent and in the adjacent segments 5 mm proximal and distal, as determined by follow-up angiography. Quality assessment was evaluated by the Meta-analysis of Observational Studies in Epidemiology guidelines [[11]Stroup D.F. Berlin J.A. Morton S.C. Olkin I. Williamson G.D. Rennie D. et al.Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.JAMA. 2000; 283: 2008-2012Crossref PubMed Scopus (14596) Google Scholar]. HR was used for comparison of subjects with the highest ADMA versus lowest category across the studies. Heterogeneity of effect sizes across studies was assessed by using the Cochrane Q statistic and the I2 statistic. All analysis was performed using STATA software (version 12.0). A total of 88 potentially relevant citations were identified in our initial literature search. After reviewing the full texts, five studies [4Lu T.M. Ding Y.A. Lin S.J. Lee W.S. Tai H.C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention.Eur. Heart J. 2003; 24: 1912-1919Crossref PubMed Scopus (170) Google Scholar, 5Cavusoglu E. Ruwende C. Chopra V. Yanamadala S. Eng C. Pinsky D.J. et al.Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography.Coron. Artery Dis. 2009; 20: 112-117Crossref PubMed Scopus (36) Google Scholar, 6Lu T.M. Chung M.Y. Lin M.W. Hsu C.P. Lin S.J. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography.Int. J. Cardiol. 2011; 153: 135-140Abstract Full Text Full Text PDF PubMed Scopus (65) Google Scholar, 7Sen N. Ozlu M.F. Akgul E.O. Kanat S. Cayci T. Turak O. et al.Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion.Atherosclerosis. 2011; 219: 304-310Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar, 8Meinitzer A. Kielstein J.T. Pilz S. Drechsler C. Ritz E. Boehm B.O. et al.Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.Clin. Chem. 2011; 57: 112-121Crossref PubMed Scopus (93) Google Scholar] met the inclusion criteria. The characteristics of the included studies are listed in Table 1. Generally, these studies had a relatively high quality (data not shown). Three studies [4Lu T.M. Ding Y.A. Lin S.J. Lee W.S. Tai H.C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention.Eur. Heart J. 2003; 24: 1912-1919Crossref PubMed Scopus (170) Google Scholar, 6Lu T.M. Chung M.Y. Lin M.W. Hsu C.P. Lin S.J. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography.Int. J. Cardiol. 2011; 153: 135-140Abstract Full Text Full Text PDF PubMed Scopus (65) Google Scholar, 7Sen N. Ozlu M.F. Akgul E.O. Kanat S. Cayci T. Turak O. et al.Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion.Atherosclerosis. 2011; 219: 304-310Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar] reported 165 cases of MACE events among 1300 participants. Pooled HR of MACEs was 2.31 (95% CI 0.97–5.46; I2 = 85.3%; p = 0.001) compared from the highest to lowest ADMA level in a random effect model (Fig. 1.1). Three studies [5Cavusoglu E. Ruwende C. Chopra V. Yanamadala S. Eng C. Pinsky D.J. et al.Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography.Coron. Artery Dis. 2009; 20: 112-117Crossref PubMed Scopus (36) Google Scholar, 6Lu T.M. Chung M.Y. Lin M.W. Hsu C.P. Lin S.J. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography.Int. J. Cardiol. 2011; 153: 135-140Abstract Full Text Full Text PDF PubMed Scopus (65) Google Scholar, 8Meinitzer A. Kielstein J.T. Pilz S. Drechsler C. Ritz E. Boehm B.O. et al.Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.Clin. Chem. 2011; 57: 112-121Crossref PubMed Scopus (93) Google Scholar] reported 531 cases of cardiovascular mortality events among 4419 patients. Pooled HR of cardiovascular mortality was 1.65 (95% CI 1.30–2.08; I2 = 17.1%; p = 0.299) compared from the highest to lowest ADMA levels in a fixed-effect model (Fig. 1.2). Four studies [5Cavusoglu E. Ruwende C. Chopra V. Yanamadala S. Eng C. Pinsky D.J. et al.Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography.Coron. Artery Dis. 2009; 20: 112-117Crossref PubMed Scopus (36) Google Scholar, 6Lu T.M. Chung M.Y. Lin M.W. Hsu C.P. Lin S.J. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography.Int. J. Cardiol. 2011; 153: 135-140Abstract Full Text Full Text PDF PubMed Scopus (65) Google Scholar, 7Sen N. Ozlu M.F. Akgul E.O. Kanat S. Cayci T. Turak O. et al.Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion.Atherosclerosis. 2011; 219: 304-310Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar, 8Meinitzer A. Kielstein J.T. Pilz S. Drechsler C. Ritz E. Boehm B.O. et al.Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.Clin. Chem. 2011; 57: 112-121Crossref PubMed Scopus (93) Google Scholar] reported 856 cases of all-cause mortality among 4569 participants. Pooled HR of all-cause mortality was 1.62 (95% CI 1.17–2.25; I2 = 75.2%; p = 0.007) compared from the highest to lowest ADMA levels in a fixed-effect model (Fig. 1.3). No evidence of publication bias for studies reporting HRs of all-cause mortality was observed based on the Begg's rank correlation test (p = 0.618) and Egger's linear regression test (p = 0.308). Sensitivity analyses demonstrated that there was little influence in the pooled effect sizes when any study is omitted (data not shown).Table 1Summary of clinical studies included in meta-analysis.Study/yearRegionDesignSubjects(% women)Age range, mean ± SD(years)ADMA comparison(μmol/L)HR (95% CI)/event type(number)Follow-up(years)Adjustment for covariatesLu et al. [4]Lu T.M. Ding Y.A. Lin S.J. Lee W.S. Tai H.C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention.Eur. Heart J. 2003; 24: 1912-1919Crossref PubMed Scopus (170) Google ScholarTaiwanProspective study153 (13.1)71 ± 8Highest vs. lowest tertile >0.62 vs. <0.505.26 (2.16–12.85) MACE (51)3Multivariate analysisCavusoglu et al. [5]Cavusoglu E. Ruwende C. Chopra V. Yanamadala S. Eng C. Pinsky D.J. et al.Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography.Coron. Artery Dis. 2009; 20: 112-117Crossref PubMed Scopus (36) Google ScholarUSAProspective study193 (0)66.2 ± 10.4 64.1 ± 9.9High vs. low tertile >1.115 vs. <1.1152.45 (1.08–5.57) total death (26) 1.81 (1.01–3.25) cardiovascular death (15)2For all-cause death: age, number of diseased coronary arteries, hs-CRP, and fibrinogen. For cardiovascular death: age, LVEF, creatinine, presence of myocardial infarction, number of diseased coronary arteries, hs-CRP, and fibrinogen.Lu et al. [6]Lu T.M. Chung M.Y. Lin M.W. Hsu C.P. Lin S.J. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography.Int. J. Cardiol. 2011; 153: 135-140Abstract Full Text Full Text PDF PubMed Scopus (65) Google ScholarTaiwanProspective study997 (37.5)41–67Highest vs. lowest tertile >0.48 vs. <0.413.37 (1.40–8.11) total death (64) 3.61 (1.24–10.51) cardiovascular death (47) 2.48 (1.23–5.00) MACE (81)2.4Age, gender, diabetes, acute coronary syndrome and hypercholesterolemia,Sen et al. [7]Sen N. Ozlu M.F. Akgul E.O. Kanat S. Cayci T. Turak O. et al.Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion.Atherosclerosis. 2011; 219: 304-310Abstract Full Text Full Text PDF PubMed Scopus (24) Google ScholarTurkeyProspective study150 (30.0)57.5 ± 9.24 (tertile 1) 57.2 ± 9.1 (tertile 2) 57.4 ± 9.0 (tertile 3)Highest vs. lowest tertile >0.78–1.60 vs. <0.721.20 (1.13–1.41) total death (17) 1.22 (1.12–1.44) MACE (33)1.0TIMI risk score, LVEF, hs-CRP, abnormal TMPGMeinitzer et al. [8]Meinitzer A. Kielstein J.T. Pilz S. Drechsler C. Ritz E. Boehm B.O. et al.Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.Clin. Chem. 2011; 57: 112-121Crossref PubMed Scopus (93) Google ScholarGermanyProspective study3229 (30.3)59–91Highest vs. lowest tertile ≥0.89 vs. <0.721.54 (1.18–2.02) Cardiovascular death (469) 1.61 (1.30–1.99) total death (749)7.7Age, sex, presence or absence of coronary heart disease on angiography, BMI, hypertension, smoking status, LDL, HDL, triglycerides, and estimated glomerular filtration rate.Abbreviations: BMI, body mass index; HR, hazard ratio; MACE, major adverse cardiac event; LVEF, left ventricular ejection fraction; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ADMA, asymmetric dimethylarginine; Hs-CRP, high sensitivity C-reactive protein; TMPG, TIMI myocardial perfusion grade. Open table in a new tab Abbreviations: BMI, body mass index; HR, hazard ratio; MACE, major adverse cardiac event; LVEF, left ventricular ejection fraction; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ADMA, asymmetric dimethylarginine; Hs-CRP, high sensitivity C-reactive protein; TMPG, TIMI myocardial perfusion grade. This meta-analysis indicated that the highest ADMA level was associated with 65% greater cardiovascular mortality and 62% greater risk of all-cause mortality events in patients undergoing PCI. However, highest ADMA level appears to not increase the risk of MACEs (HR 2.31; 95% CI 0.97–5.46). Elevated ADMA level and subsequent cardiovascular event risk also found in other studies which did not meet our inclusion criteria for the meta-analysis. Elevated ADMA level was independently associated with the development of restenosis (HR 5.96, 95% CI: 2.45–11.26) among patients undergoing primary PCI in a case–control study [[9]Derkacz A. Protasiewicz M. Poreba R. Doroszko A. Poreba M. Antonowicz-Juchniewicz J. et al.Plasma asymmetric dimethylarginine predicts restenosis after coronary angioplasty.Arch. Med. Sci. 2010; 7: 444-448Google Scholar]. In another case–control study [[10]Ari H. Ari S. Erdogan E. Tiryakioglu O. Ustundag Y. Huysal K. et al.A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine.Heart Vessels. 2010; 25: 19-26Crossref PubMed Scopus (10) Google Scholar], high levels of ADMA were correlated with a 3.02-fold increased risk of restenosis and 2.83-fold MACEs among patients who undergo primary PCI. Elevated ADMA level and cardiovascular and all-cause mortality risk were also found in patients with coronary artery disease [12Schnabel R. Blankenberg S. Lubos E. Lackner K.J. Rupprecht H.J. Espinola-Klein C. et al.Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene study.Circ. Res. 2005; 97: e53-e59Crossref PubMed Google Scholar, 13Siegerink B. Maas R. Vossen C.Y. Schwedhelm E. Koenig W. Boger R. et al.Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study.Clin. Res. Cardiol. 2013; 102: 193-202Crossref PubMed Scopus (56) Google Scholar] and acute myocardial infarction [[14]Zeller M. Korandji C. Guilland J.C. Sicard P. Vergely C. Lorgis L. et al.Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction.Arterioscler. Thromb. Vasc. Biol. 2008; 28: 954-960Crossref PubMed Scopus (72) Google Scholar]. Several mechanisms might explain by which higher ADMA levels increase risk of MACEs or mortality. ADMA is an endogenous inhibitor of endothelial NO synthase that competes with l-arginine as a substrate for NO synthase [15Vallance P. Leone A. Calver A. Collier J. Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure.Lancet. 1992; 339: 572-575Abstract PubMed Scopus (1931) Google Scholar, 16Cooke J.P. Does ADMA cause endothelial dysfunction?.Arterioscler. Thromb. Vasc. Biol. 2000; 20: 2032-2037Crossref PubMed Scopus (540) Google Scholar]. ADMA inhibits vascular NO production at concentrations found in pathophysiological conditions [[17]Boger R.H. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.Vasc. Med. 2005; 10: S19-S25Crossref PubMed Scopus (95) Google Scholar], leading to disruption of the integrity of endothelium and subsequent atherosclerosis. Higher level of ADMA in acute coronary syndrome may be a result of inflammation [[7]Sen N. Ozlu M.F. Akgul E.O. Kanat S. Cayci T. Turak O. et al.Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion.Atherosclerosis. 2011; 219: 304-310Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar]. It should be noted that renal impairment would be partly responsible for ADMA elevation in coronary heart disease [[18]Wang J. Sim A.S. Wang X.L. Salonikas C. Naidoo D. Wilcken D.E. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease.Atherosclerosis. 2006; 184: 383-388Abstract Full Text Full Text PDF PubMed Scopus (76) Google Scholar]. Several potential limitations should be noted. First, patients in the individual study used a single value of baseline ADMA, and differential ADMA levels after PCI and during follow-up were unavailable. Second, individual studies did not adjust for potential risk factors in a consistent way; some residual confounding factors such as renal function, blood glucose, and insulin resistance could affect the results. Third, follow-up duration in most studies was less than 3 years. It is difficult to determine beyond the duration of follow-up with respect to long-term impact. Finally, most of the patients were male in the current meta-analysis; therefore, we could not determine if there were any differences between genders. In conclusion, this meta-analysis indicates that higher ADMA level is associated with an increase future risk of cardiovascular and all-cause mortality, but not for MACEs. Determination of ADMA might provide a simple method for assessment of prognosis in patients with undergoing PCI. However, these findings need to be further confirmed by larger and prospective studies. None declared.